Novartis gets CDSCO panel go ahead for Asciminib Phase 3 trial

  |  

Overview

In a significant development, major drug-maker Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of Asciminib, a Tyrosine Kinase Inhibitor (TKI) for the treatment of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.

This came in wake of the Phase III clinical trial protocol presented by Novartis at the recent SEC meeting for Oncology and Haematology.

For more details, check out the full story on the link below:

Novartis Gets CDSCO Panel Nod To Conduct Phase 3 Study Of Anti-Cancer Drug Asciminib

Speakers

Roshni Dhar

Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be reached at editorial@medicaldialogues.in.
novartis anticancer asciminib leukemia CDSCO cancer